MAGE-1/heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo

Cancer Immunology, Immunotherapy

Volumn 55, Issue 7, 2006, Pages 841-849

  Ge, Wei ^a   Sui, Yan Fang ^a   Wu, Dao Cheng ^b   Sun, Yu Jing ^a   Chen, Guang Sheng ^a   Li, Zeng Shan ^a   Si, Shao Yan ^a   Hu, Pei Zhen ^a   Huang, Yang ^a   Zhang, Xiu Min ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; INTERLEUKIN 2; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; EMULSIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP70 HEAT-SHOCK PROTEINS; IMMUNITY, CELLULAR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; VACCINATION; VACCINES, SYNTHETIC; VEHICLES;

EID: 33645323742     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0073-y     Document Type: Article

References (23)

1. Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19:2666
2. Boon T, Old LJ (1997) Cancer tumor antigens. Curr Opin Immunol 9:681
3. Cheville JC, Roche PC (1999) MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors. Mod Pathol 12:974
4. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360
5. Flynn GC, Pohl J, Flocco MT, Rothman JE (1991) Peptide-binding specificity of the molecular chaperone BiP. Nature 353:726
6. Kawakami S, Yamashita F, Hashida M (2000) Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliv Rev 45:77
7. Ma JH, Sui YF, Ye J, Ya-Yu Huang, Zeng-Shan Li, Guang-Sheng Chen, Ping Qu, Hong-Ping Song, Xiu-Min Zhang (2005) Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54:907
8. Manmohan Singh, Derek O'Hagan (1999) Advances in vaccine adjuvants. Nat Biotechnol 17:1075
9. Melief CJ, Kast WM (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167
10. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target specific nanoparticles: theory to practice. Pharmacol Rev 53:283
11. Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young KS, Chang J, Hamouda T, Olszewski MA, Baker JR Jr (2003) Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemlsion. Vaccine 21:3801
12. Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9:1647
13. Pan G, Shawer M, Oie S, Lu DR (2003) In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system. Pharm Res 20:738
14. Serguei V, Vinogradov, Tatiana K, Bronich, Alexander V Kabanov (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties, and interactions with cells. Adv Drug Deliv Rev 54:135
15. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723
16. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. J Orthop Res 15:128
17. Sun YJ, Wu DC, Cao YX, Sui YF (2005) Preparation and characterization of nanoemulsion. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21:69
18. Suzue K, Young RA (1996) Adjuvant-free Mycobacterium tuberculosis hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 156:873
19. Suzue K, Zhou X, Eisen HN, Young RA (1997) Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94:13146
20. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684
21. Wu H, Ramachandran C, Bielinska AU, Kingzett K, Sun R, Weiner ND, Rossler BJ (2001) Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int J Pharm 221:23
22. Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF (2004) Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53:825
23. Zhu X, Zhao X, Burkholder WF, Gragerov A, Ogata CM, Gottesman ME, Hendrickson WA (1996) Structural analysis of substrate binding by the molecular chaperone DnaK. Science 272:1606